In the latest quarter, 10 analysts provided ratings for Tandem Diabetes Care (NASDAQ:TNDM), showcasing a mix of bullish and bearish perspectives.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.0, a high estimate of $63.00, and a low estimate of $20.00. This current average represents a 26.79% decrease from the previous average price target of $46.44.

Exploring Analyst Ratings: An In-Depth Overview

An in-depth analysis of recent analyst actions unveils how financial experts perceive Tandem Diabetes Care. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

To gain a panoramic view of Tandem Diabetes Care's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Tandem Diabetes Care analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Tandem Diabetes Care Better

Financial Milestones: Tandem Diabetes Care's Journey

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Positive Revenue Trend: Examining Tandem Diabetes Care's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 43.62% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Tandem Diabetes Care's net margin excels beyond industry benchmarks, reaching 0.27%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Tandem Diabetes Care's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.3%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Tandem Diabetes Care's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.08%, the company showcases efficient use of assets and strong financial health.

Debt Management: Tandem Diabetes Care's debt-to-equity ratio surpasses industry norms, standing at 1.8. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

What Are Analyst Ratings?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.